Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Circulation

• Publication date

  2011-08-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.110.015453PMID 21810659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.

  2011cited by this paper
• Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.

  2010cited by this paper
• Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.

  2010cited by this paper
• Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis.

  2010cited by this paper
• Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

  2010cited by this paper
• An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials

  2010cited by this paper
• Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus.

  2010cited by this paper
• SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent.

  2010cited by this paper
• Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

  2010cited by this paper
• The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.

  2009cited by this paper
• A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial.

  2009cited by this paper
• Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.

  2009cited by this paper
• Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.

  2008cited by this paper
• Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.

  2008cited by this paper
• Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions

  2008cited by this paper
• Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.

  2008cited by this paper
• A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.

  2008cited by this paper
• Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.

  2007cited by this paper
• Thrombosis in Coronary Drug-Eluting Stents: Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006*

  2007cited by this paper
• One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.

  2007cited by this paper
• A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.

  2006cited by this paper
• Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes

  2006cited by this paper
• Design and Analysis of Clinical Trials

  2006cited by this paper
• Drug-eluting Stents in Diabetic Patients

  2006cited by this paper
• Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era.

  2005cited by this paper
• Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.

  2005cited by this paper
• Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.

  2005cited by this paper
• Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial

  2005cited by this paper
• Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents

  2005cited by this paper
• Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome.

  1999cited by this paper
• Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study.

  1997cited by this paper
• Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.

  1996cited by this paper
• Design and analysis of clinical trials.

  1988cited by this paper

• Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.

  2026cites this paper
• Patient-tailored stent: Are we there yet?

  2025influential citation
• Contemporary Percutaneous Coronary Intervention in Diabetic Patients

  2025cites this paper
• Randomized clinical trial of abluminus DES+ sirolimus‐eluting stent versus everolimus‐eluting DES for percutaneous coronary intervention in patients with diabetes mellitus: An optical coherence tomography study

  2023cites this paper
• Percutaneous Coronary Intervention with Everolimus-Eluting Versus Sirolimus-Eluting Stents in Diabetic Patients Presented with Acute Coronary Syndromes: A Short-term Comparative Clinical Outcome Study

  2022cites this paper
• Diabetes and restenosis

  2022cites this paper
• Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy.

  2022cites this paper
• Angiographic and clinical outcomes in patients with versus without diabetes mellitus after revascularization with BioMime sirolimus-eluting stent

  2022cites this paper
• Comparison of Different Types of Drug-Eluting Stents for De Novo Long Coronary Artery Lesions

  2022cites this paper
• Two-year safety and efficacy of Indigenous Abluminus Sirolimus Eluting Stent. Does it differ amongst diabetics? – Data from en-ABLe- REGISTRY

  2021cites this paper
• A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients

  2021cites this paper
• Coronary revascularization in patients with stable coronary disease and diabetes mellitus

  2021cites this paper
• Percutaneous Coronary Intervention in Diabetic Patients

  2020cites this paper
• Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes Based on the Hemoglobin A1c Level

  2020cites this paper
• Clinical impact of diabetes mellitus on 2-year clinical outcomes following PCI with second-generation drug-eluting stents; Landmark analysis findings from patient registry: Pooled analysis of the Korean multicenter drug-eluting stent registry

  2020cites this paper
• Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis.

  2020cites this paper
• Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario

  2020cites this paper
• Comparative clinical evaluation of safety and efficacy of commonly used drug-eluting stents in coronary artery disease patients after angioplasty in South India: A retro-prospective multi-center study

  2019influential citation
• Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents

  2019cites this paper
• Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial

  2019cites this paper
• Actualización en cardiología intervencionista

  2018cites this paper
• Merging the properties of a sirolimus coated balloon with those of a bioresorbable polymer sirolimus eluting stent to address the "diabetes issue". Results from the En-Abl multicenter registry.

  2018cites this paper
• Safety and efficacy of zotarolimus‐eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE‐DIABETES CHINA Study

  2018cites this paper
• Second-generation versus first-generation drug-eluting stents in patients with and without diabetes mellitus: pooled analysis from the RESET and NEXT trials

  2018cites this paper
• Midterm angiographic outcomes with sirolimus- and everolimus-eluting stents for small vessels in diabetic patients: propensity-score-matched comparisons in three different vessel diameters

  2018cites this paper
• Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOlving Stent Technology

  2018cites this paper
• en cardiología intervencionista

  2018cites this paper
• Percutaneous coronary intervention vs. cardiac surgery in diabetic patients. Where are we now and where should we be going?

  2017cites this paper
• Contemporary Drug-Eluting Stents and Vascular Response

  2017cites this paper
• Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA)

  2017cites this paper
• Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.

  2017cites this paper
• 7.28 Drug Eluting Stents

  2017cites this paper
• Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.

  2017cites this paper
• Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOlving Stent Technology.

  2017cites this paper
• A mixed treatment comparison for short- and long-term outcomes of bare-metal and drug-eluting coronary stents.

  2016cites this paper
• Increment of HFABP Level in Coronary Artery In-Stent Restenosis Segments in Diabetic and Nondiabetic Minipigs: HFABP Overexpression Promotes Multiple Pathway-Related Inflammation, Growth and Migration in Human Vascular Smooth Muscle Cells

  2016cites this paper
• PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.

  2016cites this paper
• Determining the Most Appropriate Mode of Coronary Artery Revascularisation in Patients With Diabetes.

  2016influential citation
• Safety and Efficacy of a Novel Everolimus-Eluting Stent System in “Real-World” Patients with Coronary Artery Disease: A Report of Preliminary Outcomes

  2016cites this paper
• Atherectomy Devices for the Treatment of Calcified Coronary Lesions.

  2016cites this paper
• Are Everolimus-Eluting Stents Associated With Better Clinical Outcomes Compared to Other Drug-Eluting Stents in Patients With Type 2 Diabetes Mellitus?

  2016cites this paper
• A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.

  2016cites this paper
• Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials

  2016cites this paper
• Long-term outcome of early percutaneous coronary intervention in diabetic patients with acute coronary syndrome: insights from the BASE ACS trial

  2016cites this paper
• Stent thrombosis and adverse cardiovascular outcomes observed between six months and five years with sirolimus-eluting stents and other drug-eluting stents in patients with Type 2 diabetes mellitus complicated by coronary artery disease

  2016cites this paper
• Desfechos clínicos tardios de pacientes diabéticos tratados com stents farmacológicos eluidores de sirolimus ou everolimus: uma análise do registro DESIRE

  2015cites this paper
• Percutaneous Coronary Interventions in Stable and Acute Coronary Syndromes: Stent technology, lesion complexity and clinical outcome

  2015cites this paper
• Comparison of the first- and second-generation limus-eluting stents for bifurcation lesions from a Korean multicenter registry.

  2015cites this paper
• A 10‐month angiographic and 4‐year clinical outcome of everolimus‐eluting versus sirolimus‐eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial)

  2015cites this paper
• Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.

  2015cites this paper
• Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus

  2015cites this paper
• Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes

  2015cites this paper
• Comparison of First- and Second-Generation Drug-Eluting Stents in an All-Comer Population of Patients with Diabetes Mellitus (from Katowice-Zabrze Registry)

  2015cites this paper
• Progress in interventional cardiology: challenges for the future

  2015cites this paper
• Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis

  2014cites this paper
• Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population.

  2014cites this paper
• Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: Above the knee).

  2014cites this paper
• Polymer-free amphilimus-eluting stents in patients with diabetes mellitus.

  2014cites this paper
• CORONARY ARTERY DISEASE Original Studies Intimal Hyperplasia and Vascular Remodeling After Everolimus-Eluting and Sirolimus-Eluting Stent Implantation in Diabetic Patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound Trial

  2014cites this paper
• Clinical impact of second-generation everolimus-eluting stents compared with first-generation drug-eluting stents in diabetic patients undergoing multivessel percutaneous coronary intervention.

  2014cites this paper
• The diabetic dilemma: which drug-eluting stent works best?

  2014cites this paper
• Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial.

  2014cites this paper
• 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.

  2014cites this paper
• Evolution of coronary stents in patients with diabetes: are clinical outcomes still

  2014cites this paper
• Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis

  2014cites this paper
• Impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 16 randomized trials.

  2014cites this paper
• One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction.

  2014cites this paper
• First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients

  2014cites this paper
• Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.

  2014cites this paper
• Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.

  2014cites this paper
• Impact of the angiographic mechanisms underlying periprocedural myocardial infarction after drug-eluting stent implantation.

  2014cites this paper
• Clinical and angiographic assessment of coronary bare-metal stent restenosis

  2014cites this paper
• Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus.

  2014cites this paper
• Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model

  2014cites this paper
• Hybrid coronary revascularization in 100 patients with multivessel coronary disease.

  2014cites this paper
• Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 2: Below the knee).

  2014cites this paper
• Percutaneous Coronary Intervention in Patients With Diabetes

  2014cites this paper
• Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.

  2014cites this paper
• Evolution of coronary stents in patients with diabetes: are clinical outcomes still improving?

  2014cites this paper
• Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug-Eluting Stents Bridge the Gap?

  2014cites this paper
• Safety and Efficacy of Second-Generation Everolimus-Eluting Stents

  2014cites this paper
• Safety and Long-Term Efficacy of Sirolimus-Eluting Stents

  2014cites this paper
• Valoración clínica y angiográfica de la reestenosis del stent coronario convencional

  2014cites this paper
• Drug-eluting stent outcomes in diabetes

  2014cites this paper
• Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.

  2013cites this paper
• Association of Body Mass Index With Major Cardiovascular Events and With Mortality After Percutaneous Coronary Intervention

  2013cites this paper
• Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention.

  2013cites this paper
• Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

  2013cites this paper
• Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

  2013cites this paper
• Comparison of Zotarolimus-Eluting stent versus Sirolimus-Eluting stent for de novo coronary artery disease in patients with diabetes mellitus from the ESSENCE-DIABETES II trial.

  2013cites this paper
• Comparison of neointimal hyperplasia and peri-stent vascular remodeling after implantation of everolimus-eluting versus sirolimus-eluting stents: intravascular ultrasound results from the EXCELLENT study

  2013cites this paper
• Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease

  2013cites this paper
• Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.

  2013cites this paper
• Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.

  2013influential citation
• Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis

  2013cites this paper
• Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET)

  2013cites this paper
• Revascularization strategies in patients with Type 2 diabetes mellitus

  2013cites this paper
• Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: intravascular ultrasound study

  2013cites this paper
• Second‐versus first‐generation “Limus”‐eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR‐TEST‐4 trial

  2013cites this paper
• An Update on Drug-Eluting Stents

  2013cites this paper